These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32019759)

  • 21. Therapeutic transformation for diabetic kidney disease.
    Tuttle KR; Cherney DZI
    Kidney Int; 2021 Feb; 99(2):301-303. PubMed ID: 33509348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of exposure response relationship of atrasentan between North American and Asian populations.
    Heerspink HJ; Makino H; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Davis JW; Idler K; Kohan DE; Liu M; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
    Diabetes Obes Metab; 2017 Apr; 19(4):545-552. PubMed ID: 27981738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
    Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan DE; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL
    Clin Pharmacol Ther; 2021 Jun; 109(6):1631-1638. PubMed ID: 33338269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.
    Koomen JV; Stevens J; Mostafa NM; Parving HH; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Aug; 20(8):2019-2022. PubMed ID: 29603851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
    Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2021 Feb; 23(2):561-568. PubMed ID: 33184931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
    Smeijer JD; Kohan DE; Webb DJ; Dhaun N; Heerspink HJL
    Curr Opin Nephrol Hypertens; 2021 Jul; 30(4):456-465. PubMed ID: 33990507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of the progression of renal injury in diabetic rodent models with preexisting renal disease with chronic endothelin A receptor blockade.
    Spires D; Poudel B; Shields CA; Pennington A; Fizer B; Taylor L; McPherson KC; Cornelius DC; Williams JM
    Am J Physiol Renal Physiol; 2018 Oct; 315(4):F977-F985. PubMed ID: 29846112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.
    Heerspink HJL; Kohan DE; de Zeeuw D
    Kidney Int; 2021 Feb; 99(2):346-349. PubMed ID: 33144213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
    Kröpelin TF; de Zeeuw D; Andress DL; Bijlsma MJ; Persson F; Parving HH; Heerspink HJ
    Clin J Am Soc Nephrol; 2015 Mar; 10(3):410-6. PubMed ID: 25568217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Light of dawn in Melbourne: SONAR and CREDENCE.
    Nangaku M
    Kidney Int; 2019 Jul; 96(1):2-4. PubMed ID: 31229029
    [No Abstract]   [Full Text] [Related]  

  • 31. Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy.
    Kang WL; Xu GS
    Sci Rep; 2016 Jan; 6():19979. PubMed ID: 26813039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease.
    Provenzano M; Andreucci M; Garofalo C; Minutolo R; Serra R; De Nicola L
    Expert Opin Investig Drugs; 2021 Mar; 30(3):253-262. PubMed ID: 33356648
    [No Abstract]   [Full Text] [Related]  

  • 33. Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy.
    Parving HH; Rossing P
    Nat Rev Nephrol; 2015 Feb; 11(2):68-70. PubMed ID: 25488854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelin receptor blockade in patients with diabetic nephropathy.
    Rabelink TJ; Kohan DE
    Contrib Nephrol; 2011; 172():235-242. PubMed ID: 21894003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy.
    Tan RJ; Zhou L; Zhou D; Lin L; Liu Y
    PLoS One; 2013; 8(11):e79963. PubMed ID: 24265790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
    Hudkins KL; Wietecha TA; Steegh F; Alpers CE
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease.
    Saleh MA; Pollock JS; Pollock DM
    J Pharmacol Exp Ther; 2011 Jul; 338(1):263-70. PubMed ID: 21471190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
    Kohan DE; Pollock DM
    Br J Clin Pharmacol; 2013 Oct; 76(4):573-9. PubMed ID: 23228194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy.
    Lin CW; Mostafa NM; L Andress D; J Brennan J; Klein CE; Awni WM
    Clin Ther; 2018 Feb; 40(2):242-251. PubMed ID: 28756065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies to tackle diabetic kidney disease.
    Batu Demir D; Cooper ME
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):348-54. PubMed ID: 27138228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.